Table 1.

Response to imatinib by indication (analysis population, N = 186)

Main indicationCR, n (%)PR, n (%)SD, n (%)PD, n (%)Unknown, n (%)Median TTP (95% CI), moPutative target
Solid tumors: sarcoma
    Synovial sarcoma (n = 16)01 (6.3)3 (18.8)11 (68.8)1 (6.3)1.1 (1.0-4.1)KIT
    Dermatofibrosarcoma protuberans (n = 12)4 (33.3)6 (50.0)01 (8.3)1 (8.3)23.9 (7.7-∞)PDGFRB
    Leiomyosarcoma (n = 11)001 (9.1)8 (72.7)2 (18.2)1.1 (1.0-2.9)KIT
    Liposarcoma (n = 11)005 (45.5)6 (54.5)02.6 (2.1-12.5)KIT
    Chondrosarcoma (n = 7)001 (14.3)5 (71.4)1 (14.3)[0.03+-4.6+]KIT
    Ewing's sarcoma (n = 4)0003 (75.0)1 (25.0)[1.0-2.6]KIT/PDGFR
    Angiosarcoma (n = 2)0002 (100)0[0.7-0.8]KIT/PDGFR
    Rhabdomyosarcoma (n = 2)0002 (100)0[0.3-0.4]*PDGFR
    Aggressive fibromatosis (n = 20)02 (10.0)8 (40.0)7 (35.0)3 (15.0)9.1 (2.9-17.0)PDGFRA
    Chordoma (n = 5)004 (80.0)01 (20.0)[2.7-33.0+]PDGFRB
    Desmoplastic small round cell tumor (n = 5)0005 (100)0[0.5-1.4]KIT, PDGFR
    Neurofibrosarcoma (n = 3)002 (66.7)01 (33.3)[0.03+-16.4]PDGFR
    Malignant schwannoma (n = 2)0001 (50.0)1 (50.0)[0.9+-1.0]*PDGFR
    Osteosarcoma (n = 2)0002 (100)0[1.0-2.8]*PDGFR
Solid tumors: nonsarcoma
    Adenoid cystic carcinoma (n = 12)006 (50.0)5 (41.7)1 (8.3)5.7 (1.0-11.7)KIT
    Mesothelioma (n = 6)0003 (50.0)3 (50.0)[0.03+-2.3]PDGFRB
    Malignant melanoma (n = 5)0004 (80.0)1 (20.0)[0.2-2.8]KIT
    Intraocular melanoma (n = 3)0003 (100)0[1.0-2.8]KIT
    Breast carcinoma (n = 2)0001 (50.0)1 (50.0)[0.03+-0.6]*KIT/PDGFR
Hematologic malignancies
    Hypereosinophilic syndrome (n = 14)5 (35.7)1 (7.1)1 (7.1)6 (42.9)1 (7.1)8.4 (2.33-∞)PDGFRA/KIT
    Multiple myeloma (n = 6)0006 (100)0[1.0-3.0]KIT
    Myelofibrosis (n = 8)005 (62.5)1 (12.5)2 (25)[0.03+-25.2+]PDGFRB
    Myeloproliferative disorders (n = 7)3 (42.9)1 (14.3)02 (28.6)1 (14.3)[0.03+-26.7+]PDGFRB
    Systemic mastocytosis (n = 5)01 (20.0)1 (20.0)03 (60.0)[0.03+-22.3+]KIT/PDGFRA
  • NOTE: Other indications included only one patient: endometrial sarcoma (PD), fibrosarcoma breast (SD), fibrosarcoma ovary (PD), ovarian sarcoma (PD), pleural sarcoma (SD), adenocarcinoma (unknown), hemangiopericytoma (PD), malignant fibrous histiocytoma (PD), malignant mesenchymoma (PD), ovarian stromal tumor (PD), ovarian carcinoma (PD), rectal carcinoma (PD), renal cell carcinoma (unknown), seminoma (PD), small cell lung cancer (PD), and thymic carcinoma (PD). The symbol “*” means that indications have only two patients each. The symbol “+” indicates a censored time to event. “∞” indicates that the upper bound of the median confidence interval is infinity. For those indications with <10 patients, only the range of time to progression is reported in the form “[min-max].” A month is calculated as 365.25 divided by 12.

    Abbreviations: TTP, time to progression; SD, stable disease; PD, progressive disease.